Research and Markets Novartis Moving Into the Major League in the Respiratory Market



Research and Markets (http://www.researchandmarkets.com/reports/c20624) has announced the addition of Respiratory Handbook 2005-15: Novartis Moving Into the Major League to their offering

The respiratory market has experienced below average growth in the last five years (CAGR, 10%) reaching $25.5bn in 2004 in the seven major pharmaceutical markets. Future growth will be essentially flat over the next 10 years (CAGR, 0.6%), estimated to reach $27.1bn in 2015. However, based on the current product pipeline, the position of the key players is expected to change dramatically.

This report looks at asthma, COPD and allergic rhinitis indications; corticosteroids, beta-2 agonists, leukotriene modifiers, antimuscarinics and antihistamines classes. It provides an overview of the current respiratory market situation, identifying the leading therapies, companies, indications and drug classes. The report analyzes the potential impact of pipeline therapies on the respiratory market , and includes sales forecasts by indication to 2015.

The respiratory market is dominated by seven multinational drug companies, with combined 2004 revenues of $18.7bn representing 73% of total sales. GlaxoSmithKline is the global leader with 2004 sales in excess of $7bn, over $4.5 billion higher than the nearest rival, Merck.

The asthma/COPD market is expected to reach $18.1bn by 2015, with sales shifting towards COPD, which will account for 42% of revenues, following the launch of new products. Roughly 50% of asthma/COPD sales will result from products currently in development, largely replacing sales lost through the patent expiries of Advair/Seretide and Singulair.

The most significant launches over the next ten years will be GSKs once-daily inhaled corticosteroid/long-acting beta-2 agonist combination "Super Advair", Novartis long-acting, dual-action bronchodilator combination product, GSKs novel intranasal corticosteroid, Allermist and Mercks Singulair/PG-D2 combination product.

For more information visit http://www.researchandmarkets.com/reports/c20624

Laura Wood
Senior Manager
Research and Markets
Fax: +353 1 4100 980





Research and Markets Novartis Moving Into the Major League in the Respiratory Market